

**In the Claims:**

Claims 4, 7-8, 12-18, 22, 25-26 and 30-39 are cancelled.

Claims 1-3, 5-6, 9-11, 19-21, 23-24 and 27-29 are pending.

1. (previously presented) A method for treating graft-versus-host disease of the mouth, comprising: swishing for at least one minute in the mouth of a patient in need of such treatment an effective amount of a liquid formulation consisting of a pharmaceutically acceptable carrier, a member selected from the group consisting of azathioprine, 6-mercaptopurine, 6-thioguanine nucleotide, a pharmaceutically acceptable salt of azathioprine, a pharmaceutically acceptable salt of 6-mercaptopurine, and a pharmaceutically acceptable salt of 6-thioguanine nucleotide.

2. (currently amended) The method of [[C]]claim 1, wherein said formulation includes a member selected from the group consisting of azathioprine, 6-mercaptopurine, and 6-thioguanine nucleotide.

3. (currently amended) The method of [[C]]claim 1, wherein said forumulation includes azathioprine or a pharmaceutically acceptable salt thereof.

4. (cancelled)

5. (currently amended) The method of [[C]]claim 3, wherein said azathioprine or a pharmaceutically acceptable salt thereof is in a solution or suspension at a concentration between 0.5 and 50 mg/ml.

6. (currently amended) The method of [[C]]claim 3, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered at a dosage between 50 and 250 mg/day.

7. - 8. (cancelled)

9. (previously presented) The method of claim 1, wherein said swishing step includes rinsing the mouth of said patient with said formulation for at least one minute; and swallowing said formulation after said step of rinsing.

10. (previously presented) The method of claim 3, wherein said swishing step includes rinsing the mouth with said formulation for at least one minute, and thereafter expectorating said formulation without swallowing.

11. (currently amended) The method of [[C]]claim 1, further comprising systemically administering an effective amount of a member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, and an immunosuppressant.

12. - 18. (cancelled)

19. (previously presented) A method for preventing graft-versus-host disease of the mouth, comprising: swishing for at least one minute in the mouth of a patient in need of such treatment an effective amount of a liquid formulation consisting of a pharmaceutically acceptable carrier, a member selected from the group consisting of azathioprine, 6-mercaptopurine, 6-thioguanine nucleotide, a pharmaceutically

acceptable salt of azathioprine, a pharmaceutically acceptable salt of 6-mercaptopurine, and a pharmaceutically acceptable salt of 6-thioguanine nucleotide.

20. (currently amended) The method of [[C]]claim 19, wherein said formulation includes a member selected from the group consisting of azathioprine, 6-mercaptopurine, and 6-thioguanine nucleotide.

21. (previously presented) The method of claim 19, wherein said formulation includes azathioprine or a pharmaceutically acceptable salt thereof.

22. (cancelled)

23. (previously presented) The method of claim 21, wherein said azathioprine or a pharmaceutically acceptable salt thereof is in a solution or suspension at a concentration between 0.5 and 50 mg/ml.

24. (previously presented) The method of claim 21, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered at a dosage between 50 and 250 mg/day.

25. - 26. (cancelled)

27. (previously presented) The method of claim 19, wherein said swishing step includes rinsing the mouth of said patient with said formulation for at least one minute; and swallowing said formulation after said step of rinsing.

28. (previously presented) The method of claim 21, wherein said swishing step includes rinsing the mouth with said formulation for at least one minute, and thereafter expectorating said formulation without swallowing.

29. (currently amended) The method of [[C]]claim 19, further comprising systemically administering an effective amount of a member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, and an immunosuppressant.

30. - 39. (cancelled)